Global Neuroendocrine Tumours Therapeutics Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Neuroendocrine Tumours Therapeutics Market
Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body. Most neuroendocrine tumours occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.
Neuroendocrine tumours therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumours are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuro endocrine tumours. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumours in developing regions is anticipated to drive global neuroendocrine tumours market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumours market.
The global neuroendocrine tumours therapeutics market is segmented on the basis of the indication, distribution channel, drug class, and geographical regions.
Based on indication, global neuroendocrine tumours therapeutics market is segmented as
Based on the geographical regions, global neuroendocrine tumours market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumours therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumours therapeutics market. Europe is the second largest market for neuroendocrine tumours therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.
Some of the players operating in the global neuroendocrine tumours therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).
In 2016, Novartis received the U.S. FDA approval for its Afinitor®(everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin
In 2014, Ipsen Biopharmaceuticals, Inc., received U.S.FDA approval for Somatuline®Depot® (lanreotide) Injection 120 mg to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients
Report Outline:
Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body. Most neuroendocrine tumours occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.
Neuroendocrine tumours therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumours are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuro endocrine tumours. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumours in developing regions is anticipated to drive global neuroendocrine tumours market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumours market.
The global neuroendocrine tumours therapeutics market is segmented on the basis of the indication, distribution channel, drug class, and geographical regions.
Based on indication, global neuroendocrine tumours therapeutics market is segmented as
- Lung NET
- Others NET
- Gastrointestinal NET
- Pancreatic NET
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Surgery
- Chemotherapy
- Radiation Therapy
Based on the geographical regions, global neuroendocrine tumours market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumours therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumours therapeutics market. Europe is the second largest market for neuroendocrine tumours therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.
Some of the players operating in the global neuroendocrine tumours therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).
In 2016, Novartis received the U.S. FDA approval for its Afinitor®(everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin
In 2014, Ipsen Biopharmaceuticals, Inc., received U.S.FDA approval for Somatuline®Depot® (lanreotide) Injection 120 mg to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients
Report Outline:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET INTRODUCTION
2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy
2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions
2.2.1. Drug Class
2.2.2. Indication
2.2.3. Distribution Channel
3. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations
4. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Somatostatin Analogues
5.1.1. Octreotide
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Lanreotide
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Pasireotide
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.2. Chemotherapeutics
5.2.1. Fluorouracil (5-FU)
5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.1.3. Market Opportunity Analysis
5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.2.3. Market Opportunity Analysis
5.2.3. Streptozocin
5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3.3. Market Opportunity Analysis
5.2.4. Capecitabine (Xeloda)
5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.4.3. Market Opportunity Analysis
5.2.5. Dacarbazine (DTIC)
5.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.5.3. Market Opportunity Analysis
5.2.6. Temozolomide (Temodar)
5.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.6.3. Market Opportunity Analysis
5.2.7. Oxaliplatin (Eloxatin)
5.2.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.7.3. Market Opportunity Analysis
5.3. Targeted Therapeutics
5.3.1. Sunitinib
5.3.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.1.3. Market Opportunity Analysis
5.3.2. Everolimus
5.3.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.2.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
6. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Lung NET
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Gastrointestinal NET
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Pancreatic NET
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis
7. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2017 – 2023
9. NORTH AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Somatostatin Analogues
9.1.1.1.1. Octreotide
9.1.1.1.2. Lanreotide
9.1.1.1.3. Pasireotide
9.1.1.2. Chemotherapeutics
9.1.1.2.1. Fluorouracil (5-FU)
9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
9.1.1.2.3. Streptozocin
9.1.1.2.4. Temozolomide (Temodar)
9.1.1.2.5. Capecitabine (Xeloda)
9.1.1.2.6. Dacarbazine (DTIC)
9.1.1.2.7. Oxaliplatin (Eloxatin)
9.1.1.3. Targeted Therapeutics
9.1.1.3.1. Sunitinib
9.1.1.3.2. Everolimus
9.1.1.4. Others
9.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Lung NET
9.1.2.2. Others NET
9.1.2.3. Gastrointestinal NET
9.1.2.4. Pancreatic NET
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Retail Pharmacies
9.1.3.2. Hospital Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
10. EUROPE NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Somatostatin Analogues
10.1.1.1.1. Octreotide
10.1.1.1.2. Lanreotide
10.1.1.1.3. Pasireotide
10.1.1.2. Chemotherapeutics
10.1.1.2.1. Fluorouracil (5-FU)
10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
10.1.1.2.3. Streptozocin
10.1.1.2.4. Temozolomide (Temodar)
10.1.1.2.5. Capecitabine (Xeloda)
10.1.1.2.6. Dacarbazine (DTIC)
10.1.1.2.7. Oxaliplatin (Eloxatin)
10.1.1.3. Targeted Therapeutics
10.1.1.3.1. Sunitinib
10.1.1.3.2. Everolimus
10.1.1.4. Others
10.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Lung NET
10.1.2.2. Others NET
10.1.2.3. Gastrointestinal NET
10.1.2.4. Pancreatic NET
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Retail Pharmacies
10.1.3.2. Hospital Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Somatostatin Analogues
11.1.1.1.1. Octreotide
11.1.1.1.2. Lanreotide
11.1.1.1.3. Pasireotide
11.1.1.2. Chemotherapeutics
11.1.1.2.1. Fluorouracil (5-FU)
11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
11.1.1.2.3. Streptozocin
11.1.1.2.4. Temozolomide (Temodar)
11.1.1.2.5. Capecitabine (Xeloda)
11.1.1.2.6. Dacarbazine (DTIC)
11.1.1.2.7. Oxaliplatin (Eloxatin)
11.1.1.3. Targeted Therapeutics
11.1.1.3.1. Sunitinib
11.1.1.3.2. Everolimus
11.1.1.4. Others
11.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Lung NET
11.1.2.2. Others NET
11.1.2.3. Gastrointestinal NET
11.1.2.4. Pancreatic NET
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Retail Pharmacies
11.1.3.2. Hospital Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
12. LATIN AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Somatostatin Analogues
12.1.1.1.1. Octreotide
12.1.1.1.2. Lanreotide
12.1.1.1.3. Pasireotide
12.1.1.2. Chemotherapeutics
12.1.1.2.1. Fluorouracil (5-FU)
12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
12.1.1.2.3. Streptozocin
12.1.1.2.4. Temozolomide (Temodar)
12.1.1.2.5. Capecitabine (Xeloda)
12.1.1.2.6. Dacarbazine (DTIC)
12.1.1.2.7. Oxaliplatin (Eloxatin)
12.1.1.3. Targeted Therapeutics
12.1.1.3.1. Sunitinib
12.1.1.3.2. Everolimus
12.1.1.4. Others
12.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Lung NET
12.1.2.2. Others NET
12.1.2.3. Gastrointestinal NET
12.1.2.4. Pancreatic NET
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Retail Pharmacies
12.1.3.2. Hospital Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Somatostatin Analogues
13.1.1.1.1. Octreotide
13.1.1.1.2. Lanreotide
13.1.1.1.3. Pasireotide
13.1.1.2. Chemotherapeutics
13.1.1.2.1. Fluorouracil (5-FU)
13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
13.1.1.2.3. Streptozocin
13.1.1.2.4. Temozolomide (Temodar)
13.1.1.2.5. Capecitabine (Xeloda)
13.1.1.2.6. Dacarbazine (DTIC)
13.1.1.2.7. Oxaliplatin (Eloxatin)
13.1.1.3. Targeted Therapeutics
13.1.1.3.1. Sunitinib
13.1.1.3.2. Everolimus
13.1.1.4. Others
13.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Lung NET
13.1.2.2. Others NET
13.1.2.3. Gastrointestinal NET
13.1.2.4. Pancreatic NET
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Retail Pharmacies
13.1.3.2. Hospital Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Pfizer Inc., (U.S)
14.2.2. Eli Lilly & Company (U.S.)
14.2.3. Novartis AG (Switzerland)
14.2.4. F. Hoffmann-La Roche Ltd.(Switzerland)
14.2.5. Ipsen (France)
14.2.6. Amgen, Inc. (U.S.)
14.2.7. Teva Pharmaceuticals, Ltd. (Israel)
14.2.8. Bristol-Myers Squibb (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET INTRODUCTION
2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy
2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions
2.2.1. Drug Class
2.2.2. Indication
2.2.3. Distribution Channel
3. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations
4. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Somatostatin Analogues
5.1.1. Octreotide
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Lanreotide
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Pasireotide
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.2. Chemotherapeutics
5.2.1. Fluorouracil (5-FU)
5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.1.3. Market Opportunity Analysis
5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.2.3. Market Opportunity Analysis
5.2.3. Streptozocin
5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3.3. Market Opportunity Analysis
5.2.4. Capecitabine (Xeloda)
5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.4.3. Market Opportunity Analysis
5.2.5. Dacarbazine (DTIC)
5.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.5.3. Market Opportunity Analysis
5.2.6. Temozolomide (Temodar)
5.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.6.3. Market Opportunity Analysis
5.2.7. Oxaliplatin (Eloxatin)
5.2.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.7.3. Market Opportunity Analysis
5.3. Targeted Therapeutics
5.3.1. Sunitinib
5.3.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.1.3. Market Opportunity Analysis
5.3.2. Everolimus
5.3.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.2.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
6. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Lung NET
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Gastrointestinal NET
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Pancreatic NET
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis
7. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2017 – 2023
9. NORTH AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Somatostatin Analogues
9.1.1.1.1. Octreotide
9.1.1.1.2. Lanreotide
9.1.1.1.3. Pasireotide
9.1.1.2. Chemotherapeutics
9.1.1.2.1. Fluorouracil (5-FU)
9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
9.1.1.2.3. Streptozocin
9.1.1.2.4. Temozolomide (Temodar)
9.1.1.2.5. Capecitabine (Xeloda)
9.1.1.2.6. Dacarbazine (DTIC)
9.1.1.2.7. Oxaliplatin (Eloxatin)
9.1.1.3. Targeted Therapeutics
9.1.1.3.1. Sunitinib
9.1.1.3.2. Everolimus
9.1.1.4. Others
9.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Lung NET
9.1.2.2. Others NET
9.1.2.3. Gastrointestinal NET
9.1.2.4. Pancreatic NET
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Retail Pharmacies
9.1.3.2. Hospital Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
10. EUROPE NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Somatostatin Analogues
10.1.1.1.1. Octreotide
10.1.1.1.2. Lanreotide
10.1.1.1.3. Pasireotide
10.1.1.2. Chemotherapeutics
10.1.1.2.1. Fluorouracil (5-FU)
10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
10.1.1.2.3. Streptozocin
10.1.1.2.4. Temozolomide (Temodar)
10.1.1.2.5. Capecitabine (Xeloda)
10.1.1.2.6. Dacarbazine (DTIC)
10.1.1.2.7. Oxaliplatin (Eloxatin)
10.1.1.3. Targeted Therapeutics
10.1.1.3.1. Sunitinib
10.1.1.3.2. Everolimus
10.1.1.4. Others
10.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Lung NET
10.1.2.2. Others NET
10.1.2.3. Gastrointestinal NET
10.1.2.4. Pancreatic NET
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Retail Pharmacies
10.1.3.2. Hospital Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Somatostatin Analogues
11.1.1.1.1. Octreotide
11.1.1.1.2. Lanreotide
11.1.1.1.3. Pasireotide
11.1.1.2. Chemotherapeutics
11.1.1.2.1. Fluorouracil (5-FU)
11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
11.1.1.2.3. Streptozocin
11.1.1.2.4. Temozolomide (Temodar)
11.1.1.2.5. Capecitabine (Xeloda)
11.1.1.2.6. Dacarbazine (DTIC)
11.1.1.2.7. Oxaliplatin (Eloxatin)
11.1.1.3. Targeted Therapeutics
11.1.1.3.1. Sunitinib
11.1.1.3.2. Everolimus
11.1.1.4. Others
11.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Lung NET
11.1.2.2. Others NET
11.1.2.3. Gastrointestinal NET
11.1.2.4. Pancreatic NET
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Retail Pharmacies
11.1.3.2. Hospital Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
12. LATIN AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Somatostatin Analogues
12.1.1.1.1. Octreotide
12.1.1.1.2. Lanreotide
12.1.1.1.3. Pasireotide
12.1.1.2. Chemotherapeutics
12.1.1.2.1. Fluorouracil (5-FU)
12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
12.1.1.2.3. Streptozocin
12.1.1.2.4. Temozolomide (Temodar)
12.1.1.2.5. Capecitabine (Xeloda)
12.1.1.2.6. Dacarbazine (DTIC)
12.1.1.2.7. Oxaliplatin (Eloxatin)
12.1.1.3. Targeted Therapeutics
12.1.1.3.1. Sunitinib
12.1.1.3.2. Everolimus
12.1.1.4. Others
12.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Lung NET
12.1.2.2. Others NET
12.1.2.3. Gastrointestinal NET
12.1.2.4. Pancreatic NET
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Retail Pharmacies
12.1.3.2. Hospital Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Somatostatin Analogues
13.1.1.1.1. Octreotide
13.1.1.1.2. Lanreotide
13.1.1.1.3. Pasireotide
13.1.1.2. Chemotherapeutics
13.1.1.2.1. Fluorouracil (5-FU)
13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
13.1.1.2.3. Streptozocin
13.1.1.2.4. Temozolomide (Temodar)
13.1.1.2.5. Capecitabine (Xeloda)
13.1.1.2.6. Dacarbazine (DTIC)
13.1.1.2.7. Oxaliplatin (Eloxatin)
13.1.1.3. Targeted Therapeutics
13.1.1.3.1. Sunitinib
13.1.1.3.2. Everolimus
13.1.1.4. Others
13.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Lung NET
13.1.2.2. Others NET
13.1.2.3. Gastrointestinal NET
13.1.2.4. Pancreatic NET
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Retail Pharmacies
13.1.3.2. Hospital Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Pfizer Inc., (U.S)
14.2.2. Eli Lilly & Company (U.S.)
14.2.3. Novartis AG (Switzerland)
14.2.4. F. Hoffmann-La Roche Ltd.(Switzerland)
14.2.5. Ipsen (France)
14.2.6. Amgen, Inc. (U.S.)
14.2.7. Teva Pharmaceuticals, Ltd. (Israel)
14.2.8. Bristol-Myers Squibb (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
